Market Place
Sourcing Support
Milestone Pharma to Present at Piper Sandler Healthcare Conference
25 Nov 2024 //
GLOBENEWSWIRE
Milestone Pharma Reports Q3 2024 Financial & Corporate Update
12 Nov 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals to Host Investor KOL Event
24 Sep 2024 //
GLOBENEWSWIRE
Milestone Partner Ji Xing Reports Positive Ph 3 Results For Etripamil In PSVT
07 Sep 2024 //
GLOBENEWSWIRE
Milestone Partner Ji Xing Pharma, Positive Result of Ph 3 Study in PSVT in China
07 Sep 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Adds Joseph Papa To Board
04 Sep 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals to Present at H.C. Wainwright Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
26 Aug 2024 //
GLOBENEWSWIRE
Milestone Pharma Reports Q2 2024 Results And Regulatory Update
08 Aug 2024 //
GLOBENEWSWIRE
Milestone® Pharmaceuticals To Present At BTIG Biotech Conference
31 Jul 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Refreshes Board of Directors
15 Jul 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals To Host KOL Event On PSVT For Investors
12 Jun 2024 //
GLOBENEWSWIRE
Milestone At Upcoming Jefferies Healthcare Conference
31 May 2024 //
GLOBENEWSWIRE
Milestone`s CARDAMYST™ NDA Accepted By FDA
29 May 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
22 May 2024 //
GLOBENEWSWIRE
Milestone Pharma Reports Q1 2024 Results, Regulatory And Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Milestone: Etripamil Data At Heart Rhythm, Stanford, ISPOR 2024
02 May 2024 //
GLOBENEWSWIRE
Milestone Announces Etripamil Data at The American College of Cardiology Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Milestone Pharma to Present at the 23rd Annual Needham Healthcare Conference
03 Apr 2024 //
GLOBENEWSWIRE
Milestone to Present Data on Etripamil at the Association Annual Conferences
01 Apr 2024 //
GLOBENEWSWIRE
Milestone Announces Resubmission of NDA for Etripamil for Treatment in PST
28 Mar 2024 //
GLOBENEWSWIRE
Milestone Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Milestone Announces Pricing of $30.0 Million Public Offering of Common Shares
29 Feb 2024 //
GLOBENEWSWIRE
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion
29 Feb 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares
28 Feb 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil
26 Feb 2024 //
GLOBENEWSWIRE
Milestone Pharma Receives Refusal to File Letter from FDA for NDA for Etripamil
26 Dec 2023 //
GLOBENEWSWIRE
Milestone to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
PR NEWSWIRE
Milestone Pharma Presents Positive Results from Phase 2 Study of Etripamil
11 Nov 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals to Host Investor and Analyst Webcast
07 Nov 2023 //
PR NEWSWIRE
Milestone Announces Submission of NDA to the U.S. FDA for Etripamil
24 Oct 2023 //
PR NEWSWIRE
Milestone Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 Oct 2023 //
PR NEWSWIRE
Milestone Announces Etripamil Study is Selected for Science Presentation
27 Sep 2023 //
PR NEWSWIRE
Milestone Pharma to Present at H.C. Wainwright 25th Investment Conference
05 Sep 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
Milestone nnounces Publication of Results from Ph3 RAPID Trial of Etripamil
20 Jun 2023 //
PR NEWSWIRE
Milestone Announces Presentation of Data from Analysis of Etripamil Nasal Spray
22 May 2023 //
PR NEWSWIRE
Milestone Pharma Reports 1Q 2023 FYR &Provides Clinical Update
11 May 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil
08 May 2023 //
PR NEWSWIRE
Milestone to Present at the 22nd Annual Needham Virtual Healthcare Conference
12 Apr 2023 //
PR NEWSWIRE
Milestone Reports Fourth Quarter and Full Year 2022 Financial Results
29 Mar 2023 //
PR NEWSWIRE
Milestone Announces $125 Million Strategic Financing with RTW Investments
28 Mar 2023 //
PR NEWSWIRE
Milestone Pharma Progresses Clinical and Regulatory Activities for Etripamil
06 Mar 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
28 Feb 2023 //
PR NEWSWIRE
Milestone to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT
29 Nov 2022 //
PRNEWSWIRE
Milestone to Present at the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
PRNEWSWIRE
Milestone Pharmaceuticals Reports Third Quarter 2022 FYR
10 Nov 2022 //
PRNEWSWIRE
Milestone Pharma Announces New Data from Phase 3 RAPID Trial of Etripamil
07 Nov 2022 //
PRNEWSWIRE
Milestone Announces Presentation of Data from PIII Trial of Etripamil
25 Oct 2022 //
PRNEWSWIRE
After 2020 flop, Milestone`s arrhythmia spray hits in phase 3
17 Oct 2022 //
FIERCEBIOTECH
Milestone to Present at the H.C. Wainwright 24th Global Investment Conference
06 Sep 2022 //
PRNEWSWIRE
Milestone Pharma Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
PR NEWSWIRE
Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference
02 Jun 2022 //
PRNEWSWIRE
Milestone Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27 May 2022 //
PRNEWSWIRE
Milestone Pharmaceuticals to Present at the H.C. Wainwright Conference
17 May 2022 //
PRNEWSWIRE
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Milestone Pharma to Present Data from PIII NODE-302 Study of Etripamil
30 Apr 2022 //
PRNEWSWIRE
Milestone Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15 Apr 2022 //
PRNEWSWIRE
Milestone Pharma to Host Virtual Key Opinion Leader Event on Etripamil
14 Apr 2022 //
PRNEWSWIRE
